• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Average number of days from receipt of high priority inspection assignment to investigator initiating the inspection

Dictionary: High priority inspection assignments are defined as: 1) Public health emergency (e.g., outbreak, trace-back), 2) User fee driven (e.g., PDUFA, MDUFMA), 3) For cause (e.g., follow-up to a compliance issue, complaint, adverse event), 4) Impending critical patent expiry, or 5) Special request

Information is current as of February 12, 2013.

Fiscal Year - 2012

Skip graphic and jump to text data

TimeTargetAverage number of days
Oct 2011N/AN/A
Nov 2011N/AN/A
Dec 2011N/AN/A
Jan 2012N/AN/A
Feb 2012N/AN/A
Mar 2012N/AN/A
Apr 2012N/A14
May 2012N/A19
Jun 2012N/A23
Jul 2012N/A17
Aug 2012N/A11
Sep 2012N/A10

Measure implemented April 2012

Footnotes

  • Measure tracked in calendar days

Average number of days from investigator initiating the high priority inspection (entering the firm) to investigator completing the inspection

Dictionary: High priority inspection assignments are defined as: 1) Public health emergency (e.g., outbreak, trace-back), 2) User fee driven (e.g., PDUFA, MDUFMA), 3) For cause (e.g., follow-up to a compliance issue, complaint, adverse event), 4) Impending critical patent expiry, or 5) Special request

Fiscal Year - 2012

Skip graphic and jump to text data

TimeTargetAverage number of days
Oct 2011N/AN/A
Nov 2011N/AN/A
Dec 2011N/AN/A
Jan 2012N/AN/A
Feb 2012N/AN/A
Mar 2012N/AN/A
Apr 2012N/A5
May 2012N/A11
Jun 2012N/A3
Jul 2012N/A6
Aug 2012N/A5
Sep 2012N/A4

Measure implemented April 2012

Footnotes

  • Measure tracked in calendar days

Average number of days from investigator completing the high priority inspection to investigator submitting the report to headquarters

Dictionary: High priority inspection assignments are defined as: 1) Public health emergency (e.g., outbreak, trace-back), 2) User fee driven (e.g., PDUFA, MDUFMA), 3) For cause (e.g., follow-up to a compliance issue, complaint, adverse event), 4) Impending critical patent expiry, or 5) Special request

Fiscal Year - 2012

Skip graphic and jump to text data

TimeTargetAverage number of days
Oct 2011N/AN/A
Nov 2011N/AN/A
Dec 2011N/AN/A
Jan 2012N/AN/A
Feb 2012N/AN/A
Mar 2012N/AN/A
Apr 2012N/A24
May 2012N/A31
Jun 2012N/A29
Jul 2012N/A19
Aug 2012N/A12
Sep 2012N/A18

Measure implemented April 2012

Footnotes

  • Measure tracked in calendar days

Average number of days from investigator initiating the routine inspection (entering the firm) to investigator completing the inspection

Dictionary: Routine inspection assignments are defined as those that are received from the Centers as "surveillance" work at the beginning of the Fiscal Year

Fiscal Year - 2012

Skip graphic and jump to text data

TimeTargetAverage number of days
Oct 2011N/AN/A
Nov 2011N/AN/A
Dec 2011N/AN/A
Jan 2012N/AN/A
Feb 2012N/AN/A
Mar 2012N/AN/A
Apr 2012N/A3
May 2012N/A2
Jun 2012N/A3
Jul 2012N/A6
Aug 2012N/A4
Sep 2012N/A1

Measure implemented April 2012

Footnotes

  • Measure tracked in calendar days

Average number of days from investigator completing the routine inspection to investigator submitting the report to headquarters

Dictionary: Routine inspection assignments are defined as those that are received from the Centers as "surveillance" work at the beginning of the Fiscal Year

Fiscal Year - 2012

Skip graphic and jump to text data

TimeTargetAverage number of days
Oct 2011N/AN/A
Nov 2011N/AN/A
Dec 2011N/AN/A
Jan 2012N/AN/A
Feb 2012N/AN/A
Mar 2012N/AN/A
Apr 2012N/A55
May 2012N/A8
Jun 2012N/A14
Jul 2012N/A28
Aug 2012N/A28
Sep 2012N/A16

Measure implemented April 2012

Footnotes

  • Measure tracked in calendar days

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.